<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Carbamazepine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00564</strong>&#160; (APRD00337)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00564/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00564/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00564.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00564.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00564.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00564.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00564.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00564">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>5-Carbamoyl-5H-dibenz(b,f)azepine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Carbamazepin</td><td>German</td><td>INN</td></tr><tr><td>Carbamazepina</td><td>Spanish</td><td>INN</td></tr><tr><td>Carbamaz&#233;pine</td><td>French</td><td>INN</td></tr><tr><td>Carbamazepinum</td><td>Latin</td><td>INN</td></tr><tr><td>CBZ</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Actebral</td><td>Sanofi-Aventis</td></tr><tr><td>Anleptic</td><td>Square</td></tr><tr><td>Biston</td><td>Zentiva</td></tr><tr><td>Carbamat</td><td>AstraZeneca</td></tr><tr><td>Carbatrol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Epitol</td><td>Teva</td></tr><tr><td>Equetro</td><td>Validus</td></tr><tr><td>Neurotop</td><td>Gerot</td></tr><tr><td>TEGretol</td><td>Novartis</td></tr><tr><td>T&#233;gr&#233;tol</td><td>Novartis</td></tr><tr><td>TEGretol Chewtabs</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>TEGretol-CR</td><td>Novartis</td></tr><tr><td>TEGretol-XR</td><td>Novartis</td></tr><tr><td>Teril</td><td>Taro</td></tr><tr><td>Timonil</td><td>Desitin</td></tr><tr><td>Versitol</td><td>Micro Synapse</td></tr><tr><td>Versizur</td><td>Micro Labs</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li>
<li><a href="/mesh/antimanic-agents">Antimanic Agents</a></li>
<li><a href="/mesh/analgesics-non-narcotic">Analgesics, Non-Narcotic</a></li></ul></td></tr><tr><th>CAS number</th><td>298-46-4</td></tr><tr><th>Weight</th><td>Average: 236.2686<br>Monoisotopic: 236.094963016</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O</td></tr><tr><th>InChI Key</th><td>FFGPTBGBLSHEPO-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene-2-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00564.gif?1265922774">show</a>(7.72 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzazepines</td></tr><tr><th>Subclass</th><td>Dibenzazepines</td></tr><tr><th>Direct parent</th><td>Dibenzazepines</td></tr><tr><th>Alternative parents</th><td>Azepines; Benzene and Substituted Derivatives; Tertiary Amines; Polyamines</td></tr><tr><th>Substituents</th><td>azepine; benzene; tertiary amine; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the dibenzazepines. These are compounds with two benzene rings connected by an azepine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of epilepsy and pain associated with true trigeminal neuralgia. </td></tr><tr><th>Pharmacodynamics</th><td>Carbamazepine, an anticonvulsant structurally similar to tricyclic antidepressants, is used to treat partial seizures, tonic-clonic seizures, pain of neurologic origin such as trigeminal neuralgia, and psychiatric disorders including manic-depressive illness and aggression due to dementia. The response to carbamazepine is variable and may be due to its variable transport, especially across the blood-brain-barrier. The transporter that may confer drug resistance is RALBP1. </td></tr><tr><th>Mechanism of action</th><td>Carbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with reduction of post-tetanic potentiation of synaptic transmission in the spinal cord. Carbamazepine also possesses anticholinergic, central antidiuretic, antiarrhythmic, muscle relaxant, antidepressant (possibly through blockade of norepinephrine release), sedative, and neuromuscular-blocking properties.</td></tr><tr><th>Absorption</th><td>In clinical studies, carbamazepine suspension, conventional tablets, and extended-release tablets delivered equivalent amounts of drug to the systemic circulation. However, it has been observed that the suspension is somewhat faster absorbed. Furthermore, the extended-release tablet is slightly slower than the conventional tablet. The bioavailability of the extended-release tablet is 89%, compared to the suspension. Plasma levels of carbamazepine are variable. The time to peak concentration for the different formulations are as follows:
Suspension = 1.5 hours;
Conventional tablets = 4-5 hours;
Extended-release tablets = 3-12 hours. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>76% bound to plasma proteins. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. CYP3A4 is the primary isoform responsible for the formation of carbamazepine-10,11-epoxide. This metabolite is active and shown to be equipotent to carbamazepine as an anticonvulsant. Carbamazepine is more rapidly metabolized to the aforementioned metabolite in younger patients than in adults. It also undergoes glucuronidation via UGT2B7, however this finding has been disputed. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Carbamazepine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00291">10,11-Epoxycarbamazepine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/292">Details</a></td></tr><tr><td>Carbamazepine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00710">3-hydroxycarbamazepine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/731">Details</a></td></tr><tr><td>Carbamazepine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00804">Carbamazepine 2,3-epoxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/825">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00710">3-hydroxycarbamazepine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET01101">2,3-Dihydroxycarbamazepine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1071">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00804">Carbamazepine 2,3-epoxide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00681">2-hydroxycarbamazepine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1073">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00681">2-hydroxycarbamazepine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00684">2-hydroxyiminostilbene</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1076">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00684">2-hydroxyiminostilbene</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01099">Carbamazepine iminoquinone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1077">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00681">2-hydroxycarbamazepine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01101">2,3-Dihydroxycarbamazepine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1184">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01101">2,3-Dihydroxycarbamazepine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00807">Carbamazepine-O-quinone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1186">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00291">10,11-Epoxycarbamazepine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004787" target="_blank">Epoxide hydrolase 1</a></li></ul></td><td><a href="/metabolites/DBMET00806">10,11-Dihydroxycarbamazepine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1234">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00804">Carbamazepine 2,3-epoxide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00710">3-hydroxycarbamazepine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1423">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>72% of the dose is in the urine while 28% is in the feces. Hydroxylated and conjugated metabolites are largely what was recovered in the urine. 3% of the dose is recovered as unchanged carbamazepine. </td></tr><tr><th>Half life</th><td>Initial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses. </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Mild ingestions cause vomiting, drowsiness, ataxia, slurred speech, nystagmus, dystonic reactions, and hallucinations. Severe intoxications may produce coma, seizures, respiratory depression, and hypotension</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Carbamazepine Metabolism Pathway</td><td>Drug metabolism</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Sodium channel protein type 1 subunit alpha<br>Gene symbol: SCN1A<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P35498" target="_blank">P35498 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs3812718" target="_blank">rs3812718 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IVS5N + 5 G&gt;A</td><td>Carbamazepine resistant therapy, higher maintenance dose</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/24052718" target="_blank" title='# Sterjev Z, Kiteva G, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska T, Nestorovska K, Matevska N, Trajkovik-Jolevska S, Dimovski A, Suturkova Lj: Influence of the SCN1A IVS5N + 5 G&gt;A Polymorphism on Therapy with Carbamazepine for Epilepsy. Balkan J Med Genet. 2012 Jun;15(1):19-24. doi: 10.2478/v10034-012-0003-1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/24052718'>24052718 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Heat shock 70 kDa protein 1-like<br>Gene symbol: HSPA1L<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P34931" target="_blank">P34931 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2227956" target="_blank">rs2227956 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T allele</td><td>Hypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16538175" target="_blank" title="Alfirevic A, Mills T, Harrington P, Pinel T, Sherwood J, Jawaid A, Smith JC, March RE, Barratt BJ, Chadwick DW, Kevin Park B, Pirmohamed M: Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics. 2006 Apr;16(4):287-96.">16538175 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Heat shock 70 kDa protein 1A/1B<br>Gene symbol: HSPA1A<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08107" target="_blank">P08107 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs506770" target="_blank">rs506770 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C allele</td><td>Hypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16538175" target="_blank" title="Alfirevic A, Mills T, Harrington P, Pinel T, Sherwood J, Jawaid A, Smith JC, March RE, Barratt BJ, Chadwick DW, Kevin Park B, Pirmohamed M: Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics. 2006 Apr;16(4):287-96.">16538175 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Heat shock 70 kDa protein 1A/1B<br>Gene symbol: HSPA1A<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08107" target="_blank">P08107 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1043620" target="_blank">rs1043620 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C allele</td><td>Hypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16538175" target="_blank" title="Alfirevic A, Mills T, Harrington P, Pinel T, Sherwood J, Jawaid A, Smith JC, March RE, Barratt BJ, Chadwick DW, Kevin Park B, Pirmohamed M: Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics. 2006 Apr;16(4):287-96.">16538175 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>HLA class I histocompatibility antigen, B-15 alpha chain<br>Gene symbol: HLA-B<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P30464" target="_blank">P30464 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs3130690" target="_blank">rs3130690 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T allele</td><td>Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16538176" target="_blank" title="Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006 Apr;16(4):297-306.">16538176 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>HLA class I histocompatibility antigen, A-31 alpha chain<br>Gene symbol: HLA-A<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P16189" target="_blank">P16189 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1264511" target="_blank">rs1264511 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>G allele</td><td>Macropapular eruption</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16538176" target="_blank" title="Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006 Apr;16(4):297-306.">16538176 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Promotilin<br>Gene symbol: MLN<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P12872" target="_blank">P12872 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2894342" target="_blank">rs2894342 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A allele</td><td>Hypersensitivity syndrome</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16538176" target="_blank" title="Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006 Apr;16(4):297-306.">16538176 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Flotillin-1<br>Gene symbol: FLOT1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/O75955" target="_blank">O75955 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs3909184" target="_blank">rs3909184 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>HLA-B*1502</td><td>G &gt; C</td><td>Patients with the CG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the CC genotype (non-carriers of HLA-b*1502)</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/18637831" target="_blank" title='# Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V: Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008 Dec;49(12):2087-91. doi: 10.1111/j.1528-1167.2008.01719.x. Epub 2008 Jul 14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18637831'>18637831 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Mucin-21<br>Gene symbol: MUC21<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q5SSG8" target="_blank">Q5SSG8 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2844682" target="_blank">rs2844682 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>HLA-B*1502</td><td>G&gt;A</td><td>Patients with the AG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the AA genotype</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/18637831" target="_blank" title='# Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V: Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008 Dec;49(12):2087-91. doi: 10.1111/j.1528-1167.2008.01719.x. Epub 2008 Jul 14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18637831'>18637831 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Flotillin-1<br>Gene symbol: FLOT1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/O75955" target="_blank">O75955 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs3909184" target="_blank">rs3909184 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>HLA-B*1502</td><td>G &gt; C</td><td>Patients with the CG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the CC genotype (non-carriers of HLA-b*1502)</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15057820" target="_blank" title='# Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT: Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004 Apr 1;428(6982):486. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15057820'>15057820 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Mucin-21<br>Gene symbol: MUC21<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q5SSG8" target="_blank">Q5SSG8 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2844682" target="_blank">rs2844682 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>HLA-B*1502</td><td>G&gt;A</td><td>Patients with the AG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the AA genotype</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15057820" target="_blank" title='# Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT: Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004 Apr 1;428(6982):486. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15057820'>15057820 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9962</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9958</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6538</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6466</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8748</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8381</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8177</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7466</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.884</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6204</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9232</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8222</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.7358</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5554
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8848
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.978
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1131 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9653
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8734
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Shire development inc</li>
<li>Validus pharmaceuticals inc</li>
<li>Taro pharmaceutical industries ltd</li>
<li>Wockhardt eu operations (swiss) ag</li>
<li>Novartis pharmaceuticals corp</li>
<li>Taro pharmaceuticals usa inc</li>
<li>Cadista pharmaceuticals inc</li>
<li>Torrent pharmaceuticals ltd</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Actavis elizabeth llc</li>
<li>Apotex inc etobicoke site</li>
<li>Inwood laboratories inc sub forest laboratories inc</li>
<li>Pliva inc</li>
<li>Usl pharma inc</li>
<li>Warner chilcott div warner lambert co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://cibasc.com">Ciba Geigy Ltd.</a></li>
<li>Coupler Enterprises Inc.</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.dsm.com">DSM Corp.</a></li>
<li>Goldline Laboratories Inc.</li>
<li><a href="http://www.hawkinsinc.com">Hawkins Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li><a href="http://www.inwoodlabs.com">Inwood Labs</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Packaging Center</li>
<li>Pharmacy Service Center</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.precisiondose.com">Precision Dose Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.shire.com">Shire Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li><a href="http://www.torrentpharma.com">Torrent Pharmaceuticals</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.validuspharma.com">Validus Pharmaceuticals</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.vistapharm.com">Vistapharm Inc.</a></li>
<li><a href="http://www.wellspringpharm.com">Wellspring Pharmaceutical</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li>
<li>Xactdose Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, extended release</td><td>Oral</td><td>100 mg, 200 mg, 300 mg</td></tr><tr><td>Suspension</td><td>Oral</td><td>100 mg/5 mL</td></tr><tr><td>Tablet</td><td>Oral</td><td>200 mg</td></tr><tr><td>Tablet, chewable</td><td>Oral</td><td>100 mg</td></tr><tr><td>Tablet, extended release</td><td>Irrigation</td><td>100 mg, 200 mg, 400 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Carbamazepine may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Carbamazepine may decrease the effect of the benzodiazepine, alprazolam.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Carbamazepine may decrease the serum concentration of aminophylline. Aminophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Carbamazepine may decrease the anticoagulant effect of anisindione by decreasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>The CYP3A4 inducer, carbamazepine, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB01238">Aripiprazole</a></td><td>Carbamazepine, a strong CYP3A4 inducer, may decrease the serum concentration of aripiprazole by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB06216">Asenapine</a></td><td>Carbamazepine is a CYP1A2 inducer that decreases asenapine's exposure by 20%. </td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of atorvastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00732">Atracurium</a></td><td>Decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Decreases levels of bendamustine by affecting CYP1A2 hepatic enzyme metabolism. May increase concentrations of active metabolites. </td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01156">Bupropion</a></td><td>Carbamazepine, a strong CYP2B6 inducer, may increase the metabolism of bupropion. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bupropion if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06772">Cabazitaxel</a></td><td>Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may increase the serum concentration of carbamazepine during the first few days of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of carbamazepine if cimetidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin may decrease the metabolism of carbamazepine. Monitor for changes in the therapeutic or adverse effects of carbamazepine if clarithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Carbamazepine may decrease the serum concentration of clozapine by increasing its metabolism. Concomitant therapy should also be avoided due to increased risk of bone marrow suppression. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Carbamazepine may decrease the therapeutic effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB06695">Dabigatran etexilate</a></td><td>P-Glycoprotein inducers such as carbamazepine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB08912">Dabrafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01406">Danazol</a></td><td>Danazol may decrease the metabolism of carbamazepine. Monitor for changes in the therapeutic and adverse effects of carbamazepine if danazol is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>The anticonvulsant, carbamazepine, decreases the effect of delavirdine.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00647">Dextropropoxyphene</a></td><td>Propoxyphene increases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Carbamazepine may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Carbamazepine may decrease the serum concentration of diltiazem by increasing its metabolism. Diltiazem may increase the serum concentration of carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if dosages are changed.</td></tr><tr><td><a href="/drugs/DB01135">Doxacurium chloride</a></td><td>Decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>The anticonvulsant, carbamazepine, may decrease the therapeutic effect of doxycycline.</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Carbamazepine may decrease the serum concentration of diphylline. Diphylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the effect of carbamazepine.</td></tr><tr><td><a href="/drugs/DB08866">Estradiol valerate/Dienogest</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Carbamazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with carbamazepine.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Carbamazepine, when used concomitantly with certain NNRTIs (ie. efavirenz), may experience a decrease in serum concentration. 

Etravirine, and other NNRTIs, when used concomitantly with carbamazepine, may experience an increase in serum concentration. 

It is recommended to avoid this combination. </td></tr><tr><td><a href="/drugs/DB04953">Ezogabine</a></td><td>Ezogabine increases the clearance of carbamazepine (30%). The mechanism of this interaction is unknown. </td></tr><tr><td><a href="/drugs/DB00949">Felbamate</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>Carbamazepine may increase the metabolism of felodipine. Monitor for changes in the therapeutic and adverse effects of felodipine if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase the therapeutic and adverse effects of carbamazepine.</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Carbamazepine may decrease the serum concentration of fluoxetine by increasing its metabolism. Fluoxetine may increase the serum concentration of carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or doses are changed.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Fluvoxamine increases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>The CYP3A4 inducer, carbamazepine, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Carbamazepine may decrease the serum concentration of haloperidol by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of haloperidol if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Carbamazepine, a strong CYP3A4 inducer, may increase the metabolism of imatinib. Imatinib, a strong CYP3A4 inhibitor, may increase the metabolism of carbamazepine. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir increases the effect and toxicity of carbamazepine</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Carbamazepine effect is increased as is isoniazid toxicity</td></tr><tr><td><a href="/drugs/DB00982">Isotretinoin</a></td><td>Isotretinoine decreases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase the effect of carbamazepine.</td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>The macrolide, josamycin, may increase the effect of carbamazepine.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase the effect of carbamazepine.</td></tr><tr><td><a href="/drugs/DB00555">Lamotrigine</a></td><td>Lamotrigine may increase the adverse effects of carbamazepine by increasing the concentration of its active metabolite, carbamazepine-epoxide. Carbamazepine may decrease the therapeutic effect of lamotrigine by increasing its metabolism. Lamotrigine doses should be adjusted accordingly. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinue or doses are changed.</td></tr><tr><td><a href="/drugs/DB01202">Levetiracetam</a></td><td>Concomitant therapy may results in additive adverse CNS effects.</td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Carbamazepine may decrease the contraceptive effect of levonorgestrel.</td></tr><tr><td><a href="/drugs/DB08882">Linagliptin</a></td><td>CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of lovastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08815">Lurasidone</a></td><td>Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. </td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>Carbamazepine may decrease the serum level of methadone. Monitor for changes in the therapeutic and adverse effects of methadone if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00422">Methylphenidate</a></td><td>Carbamazepine may decrease the effect of methylphendiate.</td></tr><tr><td><a href="/drugs/DB01336">Metocurine</a></td><td>Decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00916">Metronidazole</a></td><td>Metronidazole increases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Carbamazepine may decrease the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01226">Mivacurium</a></td><td>Decrease the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone increases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Carbamazepine may decrease the serum concentration of oxtriphylline. Oxtriphylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01062">Oxybutynin</a></td><td>Oxybutynin may cause carbamazepine toxicity</td></tr><tr><td><a href="/drugs/DB01337">Pancuronium</a></td><td>Decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01058">Praziquantel</a></td><td>Markedly lower praziquantel levels</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB08896">Regorafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. </td></tr><tr><td><a href="/drugs/DB00734">Risperidone</a></td><td>Decreases the effect of risperidone</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir increases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. </td></tr><tr><td><a href="/drugs/DB06201">Rufinamide</a></td><td>Decrease concentration of rufinamide thus monitor therapy </td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Sertraline increases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Carbamazepine, a p-glycoprotein inducer, may decrease the effect of simvastatin by increasing its efflux. Monitor for changes in the therapeutic and adverse effects of simvastatin if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01268">Sunitinib</a></td><td>Possible decrease in sunitinib levels</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Co-administration may cause decreased Telithromycin and increased Carbemazepine plasma concentrations. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Carbamazepine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Carbamazepine may decrease the serum concentration of theophylline. Theophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine increases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Concomitant use may result in decreased Tipranavir and increased Carbamazepine concentrations. </td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Carbamazepine is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. </td></tr><tr><td><a href="/drugs/DB00273">Topiramate</a></td><td>Carbamazepine may decrease the effectiveness of Topiramate by increase its clearance. Monitor for changes in the therapeutic and adverse effects of Topiramate if Carbamazepine is initiated, discontinued or dose changed. Adverse effects related to CNS depression have also been observed during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Carbamazepine may decrease the effect of tramadol by increasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inducer, Carbamazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The strong CYP2C8 inducer, Carbamazepine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Carbamazepine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Carbamazepine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01361">Troleandomycin</a></td><td>The macrolide, troleandomycin, may increase the effect of carbamazepine.</td></tr><tr><td><a href="/drugs/DB01199">Tubocurarine</a></td><td>Decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB08867">Ulipristal</a></td><td>Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. </td></tr><tr><td><a href="/drugs/DB00313">Valproic Acid</a></td><td>Decreases the effect of valproic acid</td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated. </td></tr><tr><td><a href="/drugs/DB01339">Vecuronium</a></td><td>Decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil may increase the serum concentration of Carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Carbamazepine if Verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06684">Vilazodone</a></td><td>Carbamazepine may increase the metabolism of Selective Serotonin Reuptake Inhibitors (SSRI). Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Carbamazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Carbamazepine may reduce serum concentrations and efficacy of voriconazole likely by increasing its metabolism. Concomitant voriconazole and carbamazepine therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Carbamazepine may decrease the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Increases the effect and toxicity of ziprasidone</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid taking grapefruit or grapefruit juice throughout treatment.</li>
<li>Grapefruit can significantly increase serum levels of this product.</li>
<li>Take with food, increases availability and reduces irritation.</li></ul></td></tr></tbody></table>